Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
公司代码NAUT
公司名称Nautilus Biotechnology Inc
上市日期Aug 07, 2020
CEOPatel (Sujal)
员工数量155
证券类型Ordinary Share
年结日Aug 07
公司地址2701 Eastlake Ave East
城市SEATTLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编98102
电话12063332001
网址https://www.nautilus.bio/
公司代码NAUT
上市日期Aug 07, 2020
CEOPatel (Sujal)